AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32894967 — intervention group
Group type: COMPARATOR
Intervention: Minimal non-pharmacological care (control)
Number of subjects: 4415
Study 32569090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone (ITHM)
Number of subjects: 233
Study 32569090 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITMO)
Number of subjects: 233
Study 34843940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg/body) administered every 2 weeks for up to 52 cycles
Number of subjects: 56
Study 34388561 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs with acupuncture
Number of subjects: 112
Study 34388561 — intervention group
Group type: COMPARATOR
Intervention: SSRIs with sham acupuncture (control group)
Number of subjects: 112
Study 34388561 — intervention group
Group type: COMPARATOR
Intervention: SSRIs alone (drug group)
Number of subjects: 112
Study 34388561 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 112
Study 33096986 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk‐based methods
Number of subjects: 0
Study 33096986 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect modeling methods
Number of subjects: 0
Study 33096986 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal treatment regime methods
Number of subjects: 0
Study 33096986 — intervention group
Group type: EXPERIMENTAL
Intervention: Model evaluation methods
Number of subjects: 0
Study 36457360 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based cognitive behavioral therapy (CBT), 10 sessions over 12 weeks with a licensed clinical psychologist, using iPads via Apple FaceTime.
Number of subjects: 46
Study 36457360 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 46
Study 32216621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive hypnotherapy (8 sessions, weekly)
Number of subjects: 45
Study 32216621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 33467878 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma choline
Number of subjects: 617
Study 33467878 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma betaine
Number of subjects: 617
Study 33467878 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trimethylamine N‐oxide
Number of subjects: 617
Study 32027862 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg every 3 weeks, extendable to 6 weeks)
Number of subjects: 60
Study 35778317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health training programs
Number of subjects: 33
Study 33293077 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Pelvic Lymph Node Dissection (EPLND)
Number of subjects: 300
Study 33293077 — intervention group
Group type: COMPARATOR
Intervention: Limited Pelvic Lymph Node Dissection (LPLND)
Number of subjects: 300
Study 33293077 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Pelvic Lymph Node Dissection (EPLND) in ISUP grade groups 3-5
Number of subjects: 300
Study 33293077 — intervention group
Group type: COMPARATOR
Intervention: Limited Pelvic Lymph Node Dissection (LPLND) in ISUP grade groups 3-5
Number of subjects: 300
Study 35926756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 71
Study 35926756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 32494060 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VR (interactive virtual environment)
Number of subjects: 30
Study 32494060 — intervention group
Group type: COMPARATOR
Intervention: Passive VR (no interaction possible with the virtual world)
Number of subjects: 30
Study 32494060 — intervention group
Group type: COMPARATOR
Intervention: No VR (black screen)
Number of subjects: 30
Study 35331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate model
Number of subjects: 419
Study 35331663 — intervention group
Group type: COMPARATOR
Intervention: Counting group
Number of subjects: 419
Study 33568366 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach training programme for GPs
Number of subjects: 14
Study 33568366 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care provided by GPs
Number of subjects: 14
Study 33568366 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training at the ICU-GP interface
Number of subjects: 14
Study 33568366 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in management of long-term complications of sepsis
Number of subjects: 14
Study 33055072 — intervention group
Group type: EXPERIMENTAL
Intervention: app-based breathing (BioBase)
Number of subjects: 75
Study 33055072 — intervention group
Group type: COMPARATOR
Intervention: mindfulness body scan
Number of subjects: 75
Study 33055072 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 75
Study 35124632 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention group (25 participants)
Number of subjects: 77
Study 35124632 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention group (25 participants)
Number of subjects: 77
Study 35124632 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 participants)
Number of subjects: 77
Study 33127212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone iontophoresis (1 mg dexamethasone per 1 g administered under the active electrode, intensity of 0.1–0.2 mA/cm2 for ten days)
Number of subjects: 46
Study 33127212 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy program (10 days)
Number of subjects: 46
Study 33087110 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT model
Number of subjects: 3000
Study 33087110 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention data
Number of subjects: 3000
Study 34081800 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible alert group
Number of subjects: 446
Study 34081800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study 34081800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 446
Study 34081800 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impact of BPA
Number of subjects: 446
Study 33191765 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable RPV
Number of subjects: 136
Study 35321938 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope-clips (OTSC) therapy
Number of subjects: 100
Study 35321938 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic treatment
Number of subjects: 100
Study 35368930 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride + Resveratrol (RES)
Number of subjects: 90
Study 35368930 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride (Control Group)
Number of subjects: 90
Study 33514384 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil (25 g/day)
Number of subjects: 72
Study 33514384 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (25 g/day)
Number of subjects: 72
Study 33514384 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (25 g/day)
Number of subjects: 72
Study 32910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized atomic-system generator (RAG) for training data sets
Number of subjects: 0
Study 32910653 — intervention group
Group type: EXPERIMENTAL
Intervention: RAG-generated training set
Number of subjects: 0
Study 32910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-dynamics simulations
Number of subjects: 0
Study 35395640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 26
Study 35395640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34563236 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or upfront surgical resection
Number of subjects: 0
Study 34563236 — intervention group
Group type: COMPARATOR
Intervention: Dopamine agonists (DA) treatment
Number of subjects: 0
Study 35472586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BIS + NOL index monitoring
Number of subjects: 60
Study 35472586 — intervention group
Group type: COMPARATOR
Intervention: Standard of care monitoring (SOC)
Number of subjects: 60
Study 34560431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined whole body vibration and resistance training (RVE)
Number of subjects: 23
Study 34560431 — intervention group
Group type: COMPARATOR
Intervention: Strength training alone (RE)
Number of subjects: 23
Study 35184077 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention for family-centered movement activities targeting strength, endurance, executive functioning, and social skills through goal-directed games and activities.
Number of subjects: 0
Study 35184077 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 0
Study 32390545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 50
Study 32390545 — intervention group
Group type: COMPARATOR
Intervention: Usual Treatment (Control)
Number of subjects: 50
Study 32588030 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical school-based physical activity module
Number of subjects: 41
Study 32588030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 34798037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg subcutaneously once every 4 weeks
Number of subjects: 359
Study 34798037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 34247578 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention sessions (n = 59)
Number of subjects: 120
Study 34247578 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 61)
Number of subjects: 120
Study 35705927 — intervention group
Group type: EXPERIMENTAL
Intervention: MHFA with RBT
Number of subjects: 0
Study 35705927 — intervention group
Group type: COMPARATOR
Intervention: MHFA alone
Number of subjects: 0
Study 33050900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks
Number of subjects: 0
Study 33050900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 35780702 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivered daily dinner tray for 6 months with assistance during meals
Number of subjects: 60
Study 35780702 — intervention group
Group type: COMPARATOR
Intervention: Regular food
Number of subjects: 60
Study 32272287 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training with active recovery (ITAR)
Number of subjects: 38
Study 32272287 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 38
Study 32272287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ITAR and CT programs
Number of subjects: 38
Study 32272287 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAR
Number of subjects: 38
Study 32272287 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 38
Study 35232755 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis with alteplase (IVT) + endovascular treatment (EVT)
Number of subjects: 600
Study 35232755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) alone
Number of subjects: 600
Study 34342505 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for identifying active pulmonary tuberculosis on chest radiographs
Number of subjects: 3327
Study 32611217 — intervention group
Group type: EXPERIMENTAL
Intervention: AI diagnosis of cancer
Number of subjects: 264
Study 32611217 — intervention group
Group type: COMPARATOR
Intervention: Physician diagnosis
Number of subjects: 264
Study 32611217 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated robotic surgery
Number of subjects: 264
Study 32611217 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of medical imaging by AI
Number of subjects: 264
Study 32097099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling training and competition (n = 13)
Number of subjects: 26
Study 32097099 — intervention group
Group type: COMPARATOR
Intervention: Recreational cycling (n = 13)
Number of subjects: 26
Study 32369856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol-based DAPT
Number of subjects: 918
Study 34314727 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent drug coated balloon (DCB)
Number of subjects: 480
Study 34314727 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 480
Study 32464630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Light Scattering (DLS) sensor at the forehead with SNR cut-off 1.66 in the first group (n = 15)
Number of subjects: 31
Study 32464630 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Light Scattering (DLS) sensor
Number of subjects: 31
Study 36411659 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement based on S-adenosyl methionine (SAMe, 200 mg/day) and probiotics (Lactobacillus helveticus Rosell®‐52, Bifidobacterium longum Rosell®‐175, 3 × 10^9 CFU/day)
Number of subjects: 80
Study 36411659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33848325 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable Composite (FC) - Filtek Z350XT Flowable Restorative
Number of subjects: 55
Study 33848325 — intervention group
Group type: COMPARATOR
Intervention: Packable Composite (PC) - Filtek Z350XT Universal Restorative
Number of subjects: 55
Study 33848325 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable Composite (FC)
Number of subjects: 55
Study 33848325 — intervention group
Group type: COMPARATOR
Intervention: Packable Composite (PC)
Number of subjects: 55
Study 33848325 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable Composite (FC) and Packable Composite (PC)
Number of subjects: 55
Study 35978339 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum acidified to pH 4.0–4.5 (AC)
Number of subjects: 15
Study 35978339 — intervention group
Group type: COMPARATOR
Intervention: Untreated pooled colostrum (MC)
Number of subjects: 15
Study 35196381 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT telephone-delivered coaching
Number of subjects: 1170
Study 33004127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1652
Study 33004127 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1652
Study 34488361 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (internal anal sphincterotomy)
Number of subjects: 250
Study 34488361 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 250
Study 32916609 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg subcutaneously once weekly
Number of subjects: 0
Study 32916609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34134591 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 20
Study 34134591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg of corn-starch)
Number of subjects: 20
Study 33983065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus doxycycline
Number of subjects: 400
Study 33983065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 36235579 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Pomace Oil (OPO)
Number of subjects: 68
Study 36235579 — intervention group
Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 68
Study 33452912 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens extract (SRE)
Number of subjects: 221
Study 33452912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 32537717 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based exercises
Number of subjects: 30
Study 32537717 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation
Number of subjects: 30
Study 35266243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.2 g/kg
Number of subjects: 0
Study 35266243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.4 g/kg
Number of subjects: 0
Study 35266243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33483355 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week educational programme on top of usual treatment
Number of subjects: 329
Study 33483355 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 329
Study 34581424 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided complete revascularization (QFR-G-CR)
Number of subjects: 229
Study 34581424 — intervention group
Group type: COMPARATOR
Intervention: IRA-only PCI (control)
Number of subjects: 229
Study 33692183 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled 6-hourly IV acetaminophen for 48 hours post-cardiac surgery
Number of subjects: 900
Study 33692183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 33232356 — intervention group
Group type: EXPERIMENTAL
Intervention: Roommates with higher BMI
Number of subjects: 104
Study 35881907 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg before PCI and 0.5 mg daily after until discharge)
Number of subjects: 451
Study 35881907 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 451
Study 35881907 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 451
Study 35881907 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 451
Study 33740975 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum family planning (PPFP) uptake
Number of subjects: 646
Study 33740975 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care wait time
Number of subjects: 646
Study 33740975 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint healthcare decision-making
Number of subjects: 646
Study 33115893 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a standing frame programme
Number of subjects: 140
Study 33115893 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 33115893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing frame programme
Number of subjects: 140
Study 32074653 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty with surgical navigation and patellar component positioning
Number of subjects: 20
Study 32648100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav
Number of subjects: 126
Study 32648100 — intervention group
Group type: COMPARATOR
Intervention: Injectable ampicillin and amikacin
Number of subjects: 126
Study 35202353 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), isoniazid (INH), and pyrazinamide (PZA)
Number of subjects: 0
Study 35202353 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month regimen for tuberculosis treatment
Number of subjects: 0
Study 34579763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hishi extract (100 mg/day)
Number of subjects: 64
Study 34579763 — intervention group
Group type: COMPARATOR
Intervention: Control (no extract)
Number of subjects: 64
Study 34219000 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg with paclitaxel 90 mg/m2
Number of subjects: 651
Study 34219000 — intervention group
Group type: COMPARATOR
Intervention: Placebo with paclitaxel 90 mg/m2
Number of subjects: 651
Study 33086156 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67
Study 33086156 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH intervention
Number of subjects: 67
Study 33787411 — intervention group
Group type: EXPERIMENTAL
Intervention: Late endovascular treatment in patients with clinical‐ASPECTS mismatch (NIHSS ≥ 10 and ASPECTS ≥ 7, or NIHSS ≥ 20 and ASPECTS ≥ 5)
Number of subjects: 337
Study 33787411 — intervention group
Group type: EXPERIMENTAL
Intervention: Late endovascular treatment in patients without clinical‐ASPECTS mismatch
Number of subjects: 337
Study 33596340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Oleic Soybean Oil (HOSBO)
Number of subjects: 60
Study 33596340 — intervention group
Group type: EXPERIMENTAL
Intervention: 80:20 blend of HOSBO and fully hydrogenated soybean oil (HOSBO+FHSBO)
Number of subjects: 60
Study 33596340 — intervention group
Group type: COMPARATOR
Intervention: 50:50 blend of palm oil and palm kernel oil (PO + PKO)
Number of subjects: 60
Study 32279030 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-then-CR
Number of subjects: 32
Study 32279030 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-then-HIIT
Number of subjects: 32
Study 32279030 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-then-HIIT (post-intervention)
Number of subjects: 32
Study 33400431 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display (HMD)
Number of subjects: 24
Study 33400431 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound-guided approach
Number of subjects: 24
Study 32336008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg once daily)
Number of subjects: 82
Study 32336008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34896069 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated decision tool and supportive interventions
Number of subjects: 212
Study 34896069 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 212
Study 33688714 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (PVP-I)
Number of subjects: 17
Study 33688714 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 17
Study 32011502 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular needling
Number of subjects: 48
Study 32011502 — intervention group
Group type: COMPARATOR
Intervention: Transverse needling
Number of subjects: 48
Study 36175936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate Ringer's solution (BRS)
Number of subjects: 400
Study 36175936 — intervention group
Group type: COMPARATOR
Intervention: Sodium lactate Ringer's solution (control group)
Number of subjects: 400